HSL Mobile App 
52 week Low
1,901.05
1,901.05
52 week High
3,054.80
3,054.80
2535.60
Day low
2,531.10
2,531.10
Day high
2,586.40
2,586.40
2535.60
Prev Close
2,579.50
2,579.50
Open
2,580.00
2,580.00
6M return
-1.18%
-1.18%
1Y return
8.34%
8.34%
MCap(Rs. in Cr.)
1,06,424.63
1,06,424.63
Total Volume
1,13,385
1,13,385
Face Value : 1
Listed Since 09 May 2023
PE Ratio
Is the price-earnings ratio for valuing a company that measures its current share price relative to its earnings per share.
P/E RATIO
52.05234
EPS
The earnings per share ratio is a portion of company's net profit allocated for each outstanding share. It is calculated by deducting preferred stock divided from the net income of the company divided by the number of outstanding shares.
EPS
49.48
PRICE/BOOK
Price-to-book ratio is used to compared the company's current market price with its book value.
PRICE/BOOK
7.71
Deliverable
These are the acutal number of shares that are traded on delivery based, meaning transfered from one person to another during the day's trade.
DELIVERABLES
76.13%
DIV YIELD.(%)
Dividend Yield measures the quantum of cash dividends paid to shareholders in a financial year relative to the market value of the per share.
DIV YIELD.(%)
0.00
Company Details
Check out the key parameters of the company to understand the financial health and stock performance
-
Technical
The key levels help you plan your entry and exit point.
-
PROFIT & LOSS
Take a quick look at the revenues and expenditure sheet.
-
Balance Sheet
Its a statement of assets, liabilities and share capital.
-
Dividend History
Check out the detailed payout data over the last three years.
-
Comparative Returns
Reveals how the stock has fared compared to the BSE, NSE benchmark indices.
Key Level
Resistance 1
2610.83
2610.83
Resistance 2
2642.17
2642.17
Support 1
2551.13
2551.13
Support 2
2522.77
2522.77
Moving Average
20 Days
2428.03
2428.03
50 Days
2379.89
2379.89
100 Days
2530.49
2530.49
200 Days
2464.98
2464.98
Growth in 3 years
Sales
32.81%
Sales Industry Avg
16.38%
PAT
33.64%
PAT Industry Avg
37.18%
32.81%
Sales Industry Avg
16.38%
PAT
33.64%
PAT Industry Avg
37.18%
| Dec 2024 ( in Cr.) | Sep 2024 ( in Cr.) | Jun 2024 ( in Cr.) | Mar 2024 ( in Cr.) | FY 2024 ( in Cr.) | |
|---|---|---|---|---|---|
| Sales | 3,230 | 3,076.51 | 2,893.42 | 2,441.10 | 10,334.77 |
| Gross Profit | 689.63 | 954.94 | 775.36 | 676.26 | 2,797.61 |
| Operating Profit | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 542.28 | 827.01 | 681.77 | 591.11 | 2,399.35 |
| Tax | 157.76 | 168.13 | 138.70 | 114.52 | 457.58 |
| Profit After Tax | 384.52 | 658.88 | 543.07 | 476.59 | 1,941.77 |
Growth in 3 years
Total Asset Growth
36.21%
Total Liabilities growth
36.21%
Reserves Change
52.46%
36.21%
Total Liabilities growth
36.21%
Reserves Change
52.46%
| Mar 2024 ( in Cr.) | Mar 2023 ( in Cr.) | Mar 2022 ( in Cr.) | Mar 2021 ( in Cr.) | Mar 2020 ( in Cr.) | |
|---|---|---|---|---|---|
| Share Capital | 40.06 | 40.06 | 40.06 | 40.06 | 40.06 |
| Reserves And Surplus | 9,323.03 | 7,395.16 | 6,115.17 | 4,681.94 | 3,445.25 |
| Investments | 2,567.92 | 1,346.42 | 1,109.47 | 1,511.97 | 829.43 |
| Total Debt | 353.27 | 293.75 | 973.23 | 321.79 | 212.67 |
| Total Liabilities | 9,929.06 | 7,917.04 | 7,289.54 | 5,184.68 | 3,884.24 |
| Total Assets | 9,929.04 | 7,917.05 | 7,289.55 | 5,184.69 | 3,884.26 |
No data available
Relative to Sensex rtn in 3 year
98.28%
Relative to Nifty rtn in 3 year
90.82%
Relative to top 3 MF rtn in 3 year
98.28%
Relative to Nifty rtn in 3 year
90.82%
Relative to top 3 MF rtn in 3 year
| 1 Year (%) | 2 Year (%) | 3 Year (%) | |
|---|---|---|---|
| Mankind Pharma | 8 | 78 | 78 |
| Bse Sensex | 8 | 33 | 39 |
| Nifty 50 | 8 | 36 | 41 |
| Nifty 500 | 7 | 48 | 48 |
Peer Companies
A quick glance on how stocks from the same sector have performed along with some key parameters
Mankind Pharma
2535.60 chg : -43.90 (-1.70%)
2535.60 chg : -43.90 (-1.70%)
Sun Pharma.Inds.
1771.00 chg : 23.60 (1.35%)
1771.00 chg : 23.60 (1.35%)
Divi`s Lab.
5900.00 chg : -11.50 (-0.19%)
5900.00 chg : -11.50 (-0.19%)
Cipla
1520.00 chg : -8.20 (-0.54%)
1520.00 chg : -8.20 (-0.54%)
Torrent Pharma.
3301.90 chg : 55.50 (1.71%)
3301.90 chg : 55.50 (1.71%)
Return Calculator
This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.
My investment would be worth 1,08,340.50 with a Gain of 8.34%
Our Research Reports
Stocks and sector-wise Research Reports by HDFC securities help you analyse, understand and take a informed investment decision.
Institutional Reports 11 Apr 2025 4:18 PM
The India Pharma & Healthcare sector is expected to see steady growth and margin improvement during Q4FY25E. We project sales/EBITDA growth of 13%/19% YoY for our coverage universe. Our assumptions a..
Institutional Reports 03 Apr 2025 12:14 PM
The US government under Trump 2.0 has announced reciprocal tariffs across countries, including ~26% tariff on imports from India. However, pharmaceutical products were exempted from the first round o..
Institutional Reports 25 Jan 2025 7:56 AM
Torrent Pharma: EBITDA (+5% YoY) growth was muted due to 3% YoY sales growth (strong 12% YoY growth in India despite the absence of Insulin CMO sales, -7% YoY in Brazil, and +4% in Germany) which was..
Report
Corporate Action
Find out the historical dividend payout and other corporate actions including bonus, stock split and rights issue etc.
No data available
Our Research Analysis
As of today
__PERCENT__%
Target Achived
__PERCENT__%
Target Achived
This call still has potential to give significant positive returns
Potential Upside
__TARGETRETURN__%
Buy Call with __TIMEFRAME__ time frame
CMP : __CMP__
Target : __TARGET__
Stop Loss : __STOPLOSS__
Reco Price : __RECOPRICE__
Reco Date :__RECODATE__
Call Type :__CALLTYPE__
__Rationale__
__RECOTYPE__ __COMPANY_NAME__
|
__DATE__
__MONTHYEAR__ |
Call initiated Target: __TARGET__ |
Target Gain __TG__ % | Reco Price: __RP__ | Stop loss: __SL__ | HORIZON : __HORIZN__ |
Our View __RECOTYPE__
FnO
A snapshot on how the stock has performed in the derivatives segment on a real-time basis.
| No data available |
MF Holdings
Here's a list of major funds which hold the stock in their portfolio as of the last reported quarter.
| Scheme Name | AUM (%) | CMV ( in Cr.) | Holding Date |
|---|---|---|---|
| No data available | |||
News
Stay tuned to the latest developments and happenings in the company.
Mankind Pharma consolidated net profit declines 16.20% in the December 2024 quarter
Net profit of Mankind Pharma declined 16.20% to Rs 380.23 crore in the quarter ended December 2024 as against Rs 453.76 crore during the previous quar....
24 Jan 2025 07:34Mankind Pharma to table results
Mankind Pharma will hold a meeting of the Board of Directors of the Company on 23 January 2025.Powered by Capital Market - Live News<....
13 Jan 2025 17:30Mankind Pharma allots 1.19 cr equity shares under QIP issue
Mankind Pharma has allotted 1,19,04,761 equity shares of face value of Re 1 each to the eligible Qualified Institutional Buyers at the issue price of ....
20 Dec 2024 14:17Mankind Pharma receives reaffirmation in credit rating from CRISIL
Mankind Pharma has received reaffirmation in credit ratings from CRISIL as under:Commercial paper (Rs 5,000 crore) - CRISIL A1 Non convertible ....
06 Nov 2024 13:15Mankind Pharma consolidated net profit rises 30.43% in the September 2024 quarter
Net profit of Mankind Pharma rose 30.43% to Rs 653.47 crore in the quarter ended September 2024 as against Rs 501.03 crore during the previous quarter....
05 Nov 2024 17:40__heading__
Published on __date__ at __time__
__description__
